Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Millendo Licenses AstraZeneca Drug

by Marc S. Reisch
January 11, 2016 | A version of this story appeared in Volume 94, Issue 2

Millendo Therapeutics, formerly known as Atterocor, has licensed a compound from AstraZeneca and raised new funding to advance research on treatments for orphan and specialty endocrine diseases. Millendo will license AstraZeneca’s AZD4901, a therapy for the treatment of polycystic ovary syndrome, a hormonal disorder whose symptoms include infertility. In exchange, AstraZeneca will receive an undisclosed up-front payment from and take an equity stake in Millendo. Separately, Millendo raised $62 million from new and existing investors including Roche. A Roche representative will join Millendo’s board.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.